medigraphic.com

2024, Number 2

<< Back Next >>

Rev Mex Anest 2024; 47 (2)

Sufentanyl: an option to the classic paradigm

Barrientos-Aderwald C, Ramírez-Rodríguez A, Contreras-Martínez Ó, García-Villasana I

Language: Spanish
References: 37
Page: 102-107
PDF size: 231.71 Kb.


ABSTRACT

Introduction: since ancient times opioids have been part of anesthesia. The development of new drugs based on the piperidine class prototype fentanyl has resulted in more potent and specific opioids. One such example is sufentanil. Sufentanil is presented as a further option for perioperative anesthetic management in different clinical scenarios from general anesthesia to sedation or critical care. Its wide therapeutic range, analgesic potency and predictable adverse effects make it a comparable or superior option to other opioids like fentanyl. The dosage recommended by the FDA and other sources are broad but in a wide variety of situations opting for the minimum effective dosage is the most recommended. Objective: a review of the pharmacokinetic and pharmacodynamic aspects of sufentanil, its applications and recommendations based on literature and clinical practice. To spread knowledge of the clinical use of sufentanil in order to promote a change in the classical paradigm of opioid use in anesthesia.Conclusions: Sufentanil is one of the best options for pain management in different clinical scenarios, from short-term procedures such as sedations to highly complex surgeries, its pharmacokinetic profile very similar to fentanyl, with a wide therapeutic margin and greater analgesic potency, make it a more than adequate option for contemporary anesthetic practice.


REFERENCES

  1. Brook K, Bennett J, Desai SP. The chemical history of morphine: an 8000-year journey, from resin to de-novo synthesis. J Anesth Hist. 2017;32:50-55. doi: 10.1016/j.janh.2017.02.001.

  2. Maciejewski D. Sufentanil in anaesthesiology and intensive therapy. Anaesthesiol Intensive Ther. 2012;44:35-41.

  3. Dayer LE, Painter JT, McCain K, King J, Cullen J, Foster HR. A recent history of opioid use in the US: Three decades of change. Subst Use Misuse. 2019;54:331-339. doi: 10.1080/10826084.2018.1517175.

  4. Leysen JE, Gommeren W, Niemegeers CJ. [3H]Sufentanil, a superior ligand for mu-opiate receptors: binding properties and regional distribution in rat brain and spinal cord. Eur J Pharmacol. 1983;87:209-225.

  5. Gropper MMA, Neal H, Cohen M, Lars I. Eriksson M, Lee A. Fleisher M, Kate Leslie MM. Miller anestesia. Vol I-II. 9th ed. (Michael A. Gropper MNHCMIEMLAFMKLMM, ed.). Elsevier; 2021.

  6. Harkouk H, Pares F, Daoudi K, Fletcher. Farmacología de los opioides. EMC-Anestesia-Reanimación. 2018;44:1-24.

  7. Zhao Y, Wu XM, Duan JL, et al. Pharmacokinetics of sufentanil administered by target-controlled infusion in Chinese surgical patients. Chin Med J. 2009;122:291-295. doi: 10.3760/cma.j.issn.0366-6999.2009.03.010

  8. Scholz J, Steinfath M, Schulz M. Clinical pharmacokinetics of alfentanil, fentanyl and sufentanil. An update. Clin Pharmacokinet. 1996;31:275-292.

  9. Stanley TH. The history and development of the fentanyl series. J Pain Symptom Manage. 1992;7:S3-7.

  10. Álvarez Y, Farré M. Farmacología de los opioides. Adicciones. 2005;17:21-40. doi: 10.1016/s1280-4703(18)89443-9.

  11. Cardoso-Ortiz J, López-Luna MA, Lor KB, Cuevas-Flores MR, Flores de la Torre JA, Covarrubias SA. Farmacología y epidemiología de opioides. Revista Bio Ciencias. 2020;7. doi: 10.15741/revbio.07.e955.

  12. Cruz MCS, Pérez GIP, Carranza ACJ. El tratamiento del dolor y los opioides. Ciencia. 2020;71:52-61.

  13. Sebel PS, Barrett CW, Kirk CJC, Heykants J. Transdermal absorption of fentanyl and sufentanil in man. European Journal of Clinical Pharmacology. 1987;32:529-531.

  14. Zou Y, Ling Y, Wei L, Tang Y, Kong G, Zhang L. The effect of a small priming dose of sufentanil on sufentanil-induced cough. J Perianesth Nurs. 2020;35:661-664. doi: 10.1016/j.jopan.2020.03.016.

  15. Highlights of prescribing information. Available in: http://www.accessdata.fda.gov/drugsatfda_docs/label/2019/019050s037lbl.pdf

  16. Fda, Cder. Highlights of prescribing information. [Accessed April 10, 2023]. Available in: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/019050s037lbl.pdf

  17. Lehmann' KA, Sipakis' K, Gasparin R, Van Peer' A. Pharmacokinetics of sufentanil in general surgical patients under different conditions of anaesthesia. Acta Anaesthesiol Scand. 1993;37:176-180.

  18. Gepts E, Shafer SL, Camu F, et al. Linearity of pharmacokinetics and model estimation of sufentanil. Anesthesiology. 1995;83:1194-204.

  19. Barash PG, Cullen BF, Stoelting RK, Cahalan MK, Stock MC. Anestesia clínica. 8a. (Llavina Núria, ed.). Wolters Kluwer; 2017.

  20. Conti G, Arcangeli A, Antonelli M et al. Sedation with sufentanil in patients receiving pressure support ventilation has no effects on respiration: a pilot study. Can J Anaesth. 2004;51:494-499.

  21. El Tahan MR, Khidr AM. Low target sufentanil effect-site concentrations allow early extubation after valve surgery. J Cardiothorac Vasc Anesth. 2013;27:63-70. doi: 10.1053/j.jvca.2012.01.023.

  22. Slepchenko G, Simon N, Goubaux B, Levron JC, Le Moing JP, Raucoules-Aimé M. Performance of target-controlled sufentanil infusion in obese patients. Anesthesiology. 2003;98:65-73. Available in: http://pubs.asahq.org/anesthesiology/article-pdf/98/1/65/405968/0000542-200301000-00014.pdf

  23. Yang XY, Xu X, Wu XM. [Effect of target-controlled infusion sufentanil in different doses combined with nitrogen monoxide inhalation on hemodynamics and postoperative recovery]. Zhonghua Yi Xue Za Zhi. 2007;87:3325-3328.

  24. Zhang L, Bao Y, Shi D. Comparing the pain of propofol via different combinations of fentanyl, sufentanil or remifentanil in gastrointestinal endoscopy. Acta Cir Bras. 2014;29:675-680. doi: 10.1590/S0102-8650201400160008

  25. Baker DE. Formulary drug review: sufentanil sublingual. Hosp Pharm. 2019;54:222-228. doi: 10.1177/0018578719851726

  26. Corder G, Castro DC, Bruchas MR, Scherrer G. Endogenous and exogenous opioids in pain. Annu Rev Neurosci. 2018;41:453-473. doi: 10.1146/annurev-neuro-080317-061522.

  27. Hua S. Advances in nanoparticulate drug delivery approaches for sublingual and buccal administration. Front Pharmacol. 2019;10:1328. doi: 10.3389/fphar.2019.01328.

  28. Van de Donk T, Ward S, Langford R, Dahan A. Pharmacokinetics and pharmacodynamics of sublingual sufentanil for postoperative pain management. Anaesthesia. 2018;73:231-237. doi: 10.1111/anae.14132.

  29. Koushik SS, Schwartz RH, Cherkalin D, Sankar V, Shaparin N, Viswanath O. A review of sublingual sufentanil tablet (SST) and its utility as an analgesic agent for pain procedures. Curr Pain Headache Rep. 2022;26:145-149. doi: 10.1007/s11916-022-01014-0.

  30. Shen T, Zheng J, Xu Z, Zhang C, Shen Y, Xu T. The 90% effective dose of sufentanil for epidural analgesia in the early first stage of labor: a double-blind, sequential dose-finding study. Clin Ther. 2021;43:1191-1200. doi: 10.1016/j.clinthera.2021.05.002

  31. Vyas N, Sahu DK, Parampill R. Comparative study of intrathecal sufentanil bupivacaine versus intrathecal bupivacaine in patients undergoing elective cesarean section. J Anaesthesiol Clin Pharmacol. 2010;26:488-492.

  32. Chen G, Gong M, Liu Y. Comparison of ropivacaine plus sufentanil and ropivacaine plus dexmedetomidine for labor epidural analgesia: a randomized controlled trial protocol. Medicine (Baltimore). 2020;99:e22113. doi: 10.1097/MD.0000000000022113.

  33. Karasawa F, Iwanov V, Moulds RF. Sufentanil and alfentanil cause vasorelaxation by mechanisms independent of the endothelium. Clin Exp Pharmacol Physiol. 1993;20:705-711.

  34. Hofbauer R, Tesinsky P, Hammerschmidt V, et al. No reduction in the sufentanil requirement of elderly patients undergoing ventilatory support in the medical intensive care unit. Eur J Anaesthesiol. 1999;16:702-707. doi: 10.1046/j.1365-2346.1999.00569.x.

  35. Wappler F, Scholz J, Prause A, Mollenberg O, Bause H, Schulte am Esch J. Stufenkonzept zur Analgosedierung in der Intensivmedizin mit Sufentanil [Level concept of analgesic dosing in intensive care medicine with sufentanil]. Anasthesiol Intensivmed Notfallmed Schmerzther. 1998;33(1):8-26.

  36. Ethuin F, Boudaoud S, Leblanc I, et al. Pharmacokinetics of long-term sufentanil infusion for sedation in ICU patients. Intensive Care Med. 2003;29:1916-1920. doi: 10.1007/s00134-003-1920-y.

  37. Nies RJ, Müller C, Pfister R, et al. Monitoring of sedation depth in intensive care unit by therapeutic drug monitoring? A prospective observation study of medical intensive care patients. J Intensive Care. 2018;6:62. doi: 10.1186/s40560-018-0331-7.




2020     |     www.medigraphic.com